Despite these promising results, indicating the potential for urinary lipocalin-2 levels as a biomarker for Crohn’s disease, further research is still needed, as another study showed that serum, but not urinary, lipocalin-2 levels were elevated in inflammatory bowel disease and correlated with disease activity [124]. This evidence concerns the gene LCN2 and inflammatory bowel disease.